Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Cellular
A soluble ActRIIB-Fc fusion protein studied in preclinical muscle and cellular signaling research models.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Recombinant Fc-fusion protein (ActRIIB extracellular domain - human IgG1 Fc; disulfide-linked homodimer)
Molecular weight
~58.4 kDa per monomer (glycosylated)
CAS number
1169766-01-1
Amino acids
343
Modification
Disulfide-linked homodimer. Each 343-residue chain comprises the ACVR2B extracellular domain (residues 1-115), a triglycyl linker (116-118), and a human IgG1 Fc (119-343); seven intrachain disulfide bridges per chain, two interchain disulfide bridges joining the two chains, and three N-glycosylation sites per chain.
A soluble decoy receptor. The extracellular ACVR2B domain binds circulating TGF-beta superfamily ligands - myostatin (GDF-8), activin A, activin B, and GDF-11 - so that they do not engage membrane-bound type II activin receptors and recruit type I receptors (ALK4/ALK5), modulating SMAD2/3 signaling in the activin-receptor pathway in skeletal muscle. The construct also binds the vascular regulators BMP-9/BMP-10, with comparatively lower affinity for BMP-2/BMP-7. The IgG1 Fc drives dimerization and confers extended circulation.
Lyophilized
20C (-80C long term)
supplied lyophilized. Lyophilized powder is stable when kept sealed and dry.
Aliquot to minimize freeze-thaw; protect from light; confirm handling against the specific lot Certificate of Analysis.
Reviews
Lee SJ. (2023). Annual Review of Physiology
Rybalka E, et al. (2020). Cells
Suh J, Lee YS. (2020). Journal of Bone Metabolism
Clinical
Campbell C, et al. (2017). Muscle & Nerve
Attie KM, et al. (2013). Muscle & Nerve
ClinicalTrials.gov (A031-01). ClinicalTrials.gov
ClinicalTrials.gov (A031-02). ClinicalTrials.gov
ClinicalTrials.gov (A031-03). ClinicalTrials.gov
ClinicalTrials.gov (A031-06). ClinicalTrials.gov
Primary research
Reichel C, et al. (2025). Drug Testing and Analysis
Lach-Trifilieff E, et al. (2014). Molecular and Cellular Biology
Pistilli EE, et al. (2011). American Journal of Pathology
Cadena SM, et al. (2010). Journal of Applied Physiology
Sako D, et al. (2010). Journal of Biological Chemistry
Zhou X, et al. (2010). Cell
Koncarevic A, et al. (2010). Endocrinology
Pistilli EE, et al. (2010). American Journal of Physiology - Regulatory, Integrative and Comparative Physiology
Lee SJ, et al. (2005). Proceedings of the National Academy of Sciences
Lee SJ, McPherron AC. (2001). Proceedings of the National Academy of Sciences
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| ACE-031This page | Recombinant Fc-fusion protein (ActRIIB extracellular domain - human IgG1 Fc; disulfide-linked homodimer) | ~58.4 kDa per monomer (glycosylated) | 1169766-01-1 |
| BPC-157 | Synthetic peptide (pentadecapeptide) | 1,419.5 g/mol | 137525-51-0 |
| TB-500 | Synthetic peptide (Thymosin Beta-4 related) | ~4,963 g/mol | 77591-33-4 |
| Epithalon | Synthetic linear tetrapeptide | 390.35 g/mol | 307297-39-8 |
| SS-31 | Synthetic aromatic-cationic tetrapeptide (C-terminally amidated, mitochondria-targeted) | 639.8 g/mol | 736992-21-5 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods